Role of GC on MACE in RA: US database analysis 26000+pts 23% on GC >90d/6mo Each 30days of GC dispensed ⏭15% increase in odds of MACE in the following 6month period! Adjustment on several confounders but not disease activity. #Abts1428 #ACR21 @RheumNow https://t.co/prdA7D5fLz https://t.co/F3wCcRAfuf

Plenary Abs#1427 #ACR21 👉🏼#Statins assoc w/ reduced #CVD & all-cause mortality, outweighing modest #T2DM risk increase in RA pts 👉🏼Reduction in all-cause mortality greater in RA than gen population 👉🏼Incr in T2DM risk is NOT greater in RA compared to gen population @RheumNow https://t.co/WcF11B0C2s

Statins in RA - plenary at #ACR21 UK Clinical Practice Research Datalink 1989-2018 @RheumNow Reduction in CVD risk, All cause mortality INCREASE in Type 2 DM risk🧐 - need to make sure we look into it for RA patients! Great work @UNMC_Rheum by Gulsen Ozen! https://t.co/YmTO0xcdjj

RA and CVD: take your statins! Obs UK study Statins ⬇️CVD HR=0.46 ⬇️All cause death HR=0.68 w/ mild ⬆️ T2DM risk HR=1.33 (but not more than in general population) ⭐️NNT to prevent CVD 102 ⭐️NNT to prevent death 46 ⭐️NNH 127 #ACR21 #Abst1427 @RheumNow https://t.co/v6TinuklNv https://t.co/r0rD4jMmuh

PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics ⭐️HR 1.39 ⭐️retrospective cohort study w/ >1300 cases Abs#1355 #ACR21 #ACRBest @RheumNow https://t.co/tL37we3lwc https://t.co/SAexvn9HMb

In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated patients, irrespective of controlled or non-controlled inflammation, as measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS

To statin or not to statin? UK cohort study 22,000 RA pts eval CV risk/diabetes w/statins Statins:⬇️CV events by 32%, ⬆️DM-2 by 33%, ⬇️all cause mortality by 54% NNT 102➡️prevent CV events NNT 42➡️prevent all cause mortality NNH 127➡️cause DM-2 absr#1427 #plenary @rheumnow https://t.co/QAt6Ie4qa7

Can’t have it all! In #RheumatoidArthritis statins when prescribed by primary care ⬇️CV mortality but sl ⬆️in type II #diabetes - just like in general pop’n-DM onset ⬆️with statins in gen pop’n #ACRBest #ACR21 @RheumNow abst#1427. https://t.co/FJ3L5w49y4

Abst 1128 Nelson & colleagues performed clustering analysis between collagen biomarkers and different phenotypes of multiple joint #OA #ACR21 @RheumNow https://t.co/J9jcSUzh7M

@BethIWallace on MACE risk with GC use in 26,239 veterans with RA. GC (>30 days in 6 months) associated 15% ⬆️in MACE. Abstr#1428 #ACR21 @RheumNow https://t.co/InXPiuO1GY

#ACR21 Abs#1428. Retrospective cohort VA study ▶️45% of patients got >30 days of GC use in a 6-month period - high # of pts! ▶️3% MACE events during study period ⭐️30 days of glucocorticoids = 15%⬆️ in odds of MACE in RA pts! @Rheumnow https://t.co/m5bl9Ho163 https://t.co/v8hdzi1Vrb

Achieving MDA in PsA results in improvements in disease activity measures, PROMs and maintenance of therapy. It may help increased work productivity and reductions in lost wages in PsA @RheumNow #ACR21 Abst#1344 https://t.co/KR1DPXt7jh https://t.co/3bfeiXxN54